USTR Urged To Pressure Canada On Revoked Drug Patents

Law360, New York (April 14, 2014, 9:17 PM ET) -- The Canadian court’s handling of drug patents has drawn the ire of Congress members, who have urged the U.S. Trade Representative to subject Canada to additional scrutiny and possible sanctions amid concerns it is invalidating branded drugs in favor of generic alternatives.

The lawmakers said in a letter Thursday that Canadian courts have revoked 18 drug patents in nine years because those courts are misinterpreting the patent utility standard, which holds that a patent has utility if it is “useful” and “capable of industrial application." The...
To view the full article, register now.